Search - tctmd.com

Displaying 501 - 520 of 674

Sort: Relevancy | Date

News Daily News

Ticagrelor Loading Dose May be Unnecessary for ACS Patients Previously on Clopidogrel

Caitlin E. Cox

January 29, 2014

News Daily News

Preconditioning May Counteract Platelet Increase Associated with RF Ablation in A-fib

L.A. McKeown

December 30, 2013

Presentation

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Presenter: Roxana Mehran

December 01, 2013

Presentation

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Presenter: Martin T. Rothman

December 01, 2013

News Conference News TCT 2013

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

November 04, 2013

Presentation TCT 2013

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Presenter: Jean-Philippe Collet

October 31, 2013

Presentation TCT 2013

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Presenter: Harvey White

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Presenter: Matthew Price

October 30, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Presenter: Laura Mauri

October 29, 2013

News Daily News

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Caitlin E. Cox

October 23, 2013

News Daily News

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

Jason Kahn

October 11, 2013

News Daily News

La Aspirina a Largo Plazo es tan Eficaz como la Terapia Doble en Pacientes SLF Sin Complicaciones

Jason Kahn

October 11, 2013

Presentation

Optimal Duration Of Dual Antiplatelet Therapy After DES Implantation

Presenter: C.W. Lee

October 10, 2013

News Daily News

Failure to Give Pre-PCI Aspirin Not Infrequent Cause of Complications

Caitlin E. Cox

October 04, 2013

News Conference News ESC 2013

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

Yael L. Maxwell

September 03, 2013

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

News Conference News ESC 2013

ACCOAST: Prasugrel Pretreatment Increases Bleeding in NSTE-ACS

Yael L. Maxwell

September 01, 2013

Advertisement

Ticagrelor Loading Dose May be Unnecessary for ACS Patients Previously on Clopidogrel

Preconditioning May Counteract Platelet Increase Associated with RF Ablation in A-fib

Is Gender a Risk Factor? Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI): Results from the Real-World PARIS Reg

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Risk Stratified Antiplatelet Therapy in ACS and During PCI: State-of-the-Art

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

La Aspirina a Largo Plazo es tan Eficaz como la Terapia Doble en Pacientes SLF Sin Complicaciones

Optimal Duration Of Dual Antiplatelet Therapy After DES Implantation

Failure to Give Pre-PCI Aspirin Not Infrequent Cause of Complications

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

ACCOAST: Prasugrel Pretreatment Increases Bleeding in NSTE-ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content